Καναδάς - Αγγλικά - Health Canada

added dimensions - caffeine - tablet - 200mg - caffeine 200mg - respiratory and cns stimulants

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; water for injections; citric acid monohydrate - cafnea injection is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Μάλτα - Αγγλικά - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - caffeine citrate - oral solution - caffeine citrate 10 mg/ml - psychoanaleptics

Κένυα - Αγγλικά - Pharmacy and Poisons Board

macarthy laboratories ltd t/a martindale pharma bamptom road harold hill romford essex rm3 8ug - caffeine citrate - solution for injection - 10mg/ml - caffeine

Κένυα - Αγγλικά - Pharmacy and Poisons Board

caffeine citrate - oral drops - 20mg/ml - caffeine

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals limited - caffeine,ribose,ubidecarenone -

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

orchid healthcare (a division of orchid chemicals & pharmaceuticals ltd.) - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules is indicated for the treatment of major depressive disorder. the efficacy of venlafaxine hydrochloride extended-release capsules in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii-r or dsm-iv category of major depressive disorder (see clinical trials ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessne

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - mexiletine hydrochloride (unii: 606d60is38) (mexiletine - unii:1u511hhv4z) - mexiletine hydrochloride 150 mg - mexiletine hydrochloride capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. mexiletine hydrochloride capsules are contraindicated in the presence of cardiogenic shock or preexisting second- or third-degree av block (if no pacemaker is present).

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n), repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - metformin hydrochloride 500 mg - repaglinide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a glinide and metformin or who have inadequate glycemic control on a glinide alone or metformin alone. limitation of use repaglinide and metformin hydrochloride tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)] - acute or chronic metabolic acidosis, including diabetic ketoacidosis. diabetic ketoacidosis should be treated with insulin [see warnings and precautions (5.1)] . - concomitant use of gemfibrozil [see drug interactions (7.2)] - known hypersensitivity to repaglinide, metformin or any inactive ingredients pregnancy category c. there are no adequate and well-control